Sanjar S, Aoki S, Boubekeur K, Burrows L, Colditz I, Chapman I, Morley J
Preclinical Research, Sandoz AG, Basel, Switzerland.
Jpn J Pharmacol. 1989 Oct;51(2):167-72. doi: 10.1254/jjp.51.167.
Intraperitoneal (i.p.) injection of platelet activating factor (PAF) in guinea pigs caused a dose-related increase in the number of eosinophils recovered from bronchoalveolar lavage fluid (BALF). The prevalence of eosinophils in BALF had significantly increased within 1 hr of i.p. injection of PAF (10 micrograms/animal) and was maximal after 24 hr. Subcutaneous osmotic mini-pumps were used to administer drugs for 5 days prior to i.p. injection of PAF (10 micrograms/animal) and for the subsequent 24 hr. The percentage increase of eosinophils in BALF, due to PAF, was inhibited in animals treated with dexamethasone, aminophylline, cromoglycate, tranilast or ketotifen, but not in animals treated with oxatomide, azelastine, amlexanox, ibudilast or AA-861. These results suggest that inhibition of pulmonary eosinophilia may be a necessary property of prophylactic anti-asthma drugs and provide indirect evidence favoring a role for PAF in eosinophilia of asthma.
豚鼠腹腔注射血小板活化因子（PAF）可导致支气管肺泡灌洗液（BALF）中回收的嗜酸性粒细胞数量呈剂量依赖性增加。腹腔注射PAF（10微克/只动物）后1小时内，BALF中嗜酸性粒细胞的比例显著增加，并在24小时后达到最大值。在腹腔注射PAF（10微克/只动物）前5天及随后24小时，使用皮下渗透微型泵给药。地塞米松、氨茶碱、色甘酸、曲尼司特或酮替芬治疗的动物中，PAF所致BALF中嗜酸性粒细胞的百分比增加受到抑制，但奥沙米特、氮卓斯汀、氨来呫诺、异丁司特或AA - 861治疗的动物中未受抑制。这些结果表明，抑制肺部嗜酸性粒细胞增多可能是预防性抗哮喘药物的必要特性，并为PAF在哮喘嗜酸性粒细胞增多中起作用提供了间接证据。
